Page 83 - Eceptor News Today

A study tested the hypothesis that the ACE-2 receptor of SARS-CoV-2 is not only an attachment factor in viral infection but also plays a role in activating the viral spike protein to facilitate membrane fusion.

A new study from scientists at La Jolla Institute for Immunology (LJI) gives researchers a guide to neutralizing Lassa virus using a trio of rare antibodies isolated from survivors of Lassa virus infection.

Researchers assessed whether loss-of-function variants of type I interferon immunity genes are associated with life-threatening COVID-19.

Researchers reported three human monoclonal antibodies generated from COVID-19-recovered individuals during the initial wave of the pandemic in India.

Researchers evaluated the vaccine effectiveness of Pfizer-BioNTech’s BNT162b2 COVID-19 vaccines against SARS-CoV-2 Omicron BA.4/5.

Researchers at University of California San Diego have identified a new signaling process involving G protein-coupled receptors (GPCRs), a cellular target already exploited by hundreds of diverse drugs.

After decades of research and two previous drug development attempts, things are looking promising for a team of University of Arizona researchers working on a less toxic treatment for a specific type of breast cancer.

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer.

A new approach to cancer immunotherapy that uses one type of immune cell to kill another-;rather than directly attacking the cancer-;provokes a robust anti-tumor immune response that shrinks ovarian, lung, and pancreatic tumors in preclinical disease models, according to researchers at the Icahn School of Medicine at Mount Sinai in New York.

Researchers summarize current knowledge about underlying mechanisms and potential therapeutic approaches for the effects of COVID-19 on the gut.